Mersana Therapeutics has been granted a patent for antibody-drug conjugates targeting human B7-H4, both in soluble and membrane-bound forms. The patent includes specific amino acid sequences for isolated antibodies that bind B7-H4, paving the way for potential therapeutics and diagnostics. GlobalData’s report on Mersana Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Mersana Therapeutics, Nanoparticle drug conjugates was a key innovation area identified from patents. Mersana Therapeutics's grant share as of May 2024 was 24%. Grant share is based on the ratio of number of grants to total number of patents.
Patent granted for antibody-drug conjugates targeting b7-h4
A recently granted patent (Publication Number: US11964024B2) discloses an isolated antibody that specifically binds to B7-H4, a protein associated with certain diseases. The antibody comprises specific amino acid sequences in its variable heavy and light chains, making it unique in its targeting ability. The patent claims cover various configurations of the isolated antibody, including monoclonal antibodies of different isotypes like IgG, as well as chimeric, humanized, or fully human versions. Additionally, the patent extends to B7-H4 antibody-drug conjugates, where the antibody is linked to drug molecules through specific linker units, enabling targeted drug delivery to B7-H4 positive diseases or disorders.
Furthermore, the patent includes claims related to methods of treating B7-H4 positive diseases, particularly cancers like breast cancer, ovarian cancer, and cholangial carcinoma, by administering the disclosed B7-H4 antibody-drug conjugates. The patent also encompasses pharmaceutical compositions containing the conjugates and outlines specific formulas for these conjugates. Notably, the patent covers cysteine-engineered antibodies and provides detailed sequences for the heavy and light chains of the isolated antibody. Overall, the patent's scope extends to a range of applications involving B7-H4 targeting antibodies, from therapeutic treatments to pharmaceutical compositions, showcasing the potential for innovative therapies in addressing B7-H4 positive conditions.
To know more about GlobalData’s detailed insights on Mersana Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
